0001567619-21-012641.txt : 20210628 0001567619-21-012641.hdr.sgml : 20210628 20210628105340 ACCESSION NUMBER: 0001567619-21-012641 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210609 FILED AS OF DATE: 20210628 DATE AS OF CHANGE: 20210628 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schutte John CENTRAL INDEX KEY: 0001713580 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-10113 FILM NUMBER: 211050967 MAIL ADDRESS: STREET 1: 9707 SHELBYVILLE ROAD CITY: LOUISVILLE STATE: KY ZIP: 40233 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACURA PHARMACEUTICALS, INC CENTRAL INDEX KEY: 0000786947 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 110853640 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 616 N. NORTH COURT, SUITE 120 CITY: PALATINE STATE: IL ZIP: 60067 BUSINESS PHONE: 847-705-7709 MAIL ADDRESS: STREET 1: 616 N. NORTH COURT, SUITE 120 STREET 2: . CITY: PALATINE STATE: IL ZIP: 60067 FORMER COMPANY: FORMER CONFORMED NAME: HALSEY DRUG CO INC/NEW DATE OF NAME CHANGE: 19920703 4 1 doc1.xml FORM 4 X0306 4 2021-06-09 0 0000786947 ACURA PHARMACEUTICALS, INC ACUR 0001713580 Schutte John 2604 RIVER GREEN CIRCLE LOUISVILLE KY 40206 0 0 1 0 Common Stock 8912655 D Common Stock 2021-06-09 4 C 0 42984375 0.16 A 42984375 I By Abuse Deterrent Pharma, LLC Warrant to Purchase Common Stock 0.528 2017-07-24 2022-07-23 Common Stock 1782531 1782531 D Warrant to Purchase Common Stock 0.01 2019-06-28 2024-06-28 Common Stock 10000000 10000000 I By Abuse Deterrent Parma, LLC Convertible Promissory Note 0.16 2021-06-09 4 C 0 6877500 0 D 2019-06-28 Common Stock 42984375 0 I By Abuse Deterrent Parma, LLC The Reporting Person is the manager and a member of AD Pharma. The Reporting Person hereby disclaims beneficial ownership of the securities, except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. On the conversion date, $6,000,000 of principal and $877,500 of interest under the note was converted into the Issuer's common stock. For each $0.16 converted, AD Pharma received one share of common stock. This note is convertible, at the election of AD Pharma, at any time prior to repayment of the note and matures on July 1, 2023. /s/ John Schutte 2021-06-24